Celon Pharma (WAR:CLN) LT-Debt-to-Total-Asset: 0.05 (As of Mar. 2026)

What is Celon Pharma LT-Debt-to-Total-Asset?

Celon Pharma WAR:CLN -0.10% 48 LT-Debt-to-Total-Asset is 0.05 as of Mar. 2026. GuruFocus rates WAR:CLN with a GF Score™ of 48/100 and a GF Value™ of zł23.11 (Modestly Undervalued). The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Celon Pharma's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.05.

Celon Pharma's long-term debt to total assets ratio increased from Mar. 2025 (0.01) to Mar. 2026 (0.05). It may suggest that Celon Pharma is progressively becoming more dependent on debt to grow their business.

Celon Pharma (WAR:CLN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Celon Pharma LT-Debt-to-Total-Asset Related Terms

Celon Pharma LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Celon Pharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celon Pharma LT-Debt-to-Total-Asset Chart

Celon Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.00

Celon Pharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.02	0.01	0.00	0.05

48GF Score

Celon Pharma SA WAR:CLN

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Celon Pharma LT-Debt-to-Total-Asset Calculation

Celon Pharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	0	/	457.46
	=

Celon Pharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	32.855	/	670.731
	=	0.05

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.05 mean?

Celon Pharma (WAR:CLN) has a LT-Debt-to-Total-Asset of 0.05 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Celon Pharma and its competitors.

Is Celon Pharma's LT-Debt-to-Total-Asset too high?

Celon Pharma's current LT-Debt-to-Total-Asset is 0.05. Overall, Celon Pharma has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Celon Pharma's LT-Debt-to-Total-Asset compare to ZTS and UTHR?

Celon Pharma's LT-Debt-to-Total-Asset of 0.05 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Celon Pharma and its competitors. Celon Pharma's current LT-Debt-to-Total-Asset is 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Celon Pharma stock overvalued right now?

Based on GuruFocus' analysis, Celon Pharma (WAR:CLN) is currently considered Modestly Undervalued. The stock's GF Value™ is zł23.11, compared to a current price of zł19.78 — trading 14.4% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.05. Celon Pharma's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Celon Pharma (WAR:CLN), the current LT-Debt-to-Total-Asset is 0.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celon Pharma (WAR:CLN) Overvalued in 2026?

Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued. The current stock price of zł19.78 is trading 14.4% below its estimated GF Value™ of zł23.11. GuruFocus considers Celon Pharma to be Modestly Undervalued.

Key valuation signals for WAR:CLN:

LT-Debt-to-Total-Asset: 0.05
GF Value™: zł23.11 vs. price of zł19.78 (14.4% below fair value)
GF Score™: 48/100 with 3 warning signs

No single metric tells the full story. See the WAR:CLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celon Pharma Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies WAR:BGD WAR:HMP WAR:MDB WAR:CBD XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR HKSE:03692 VTRS NSE:DIVISLAB OSTO:SOBI NBIX NSE:TORNTPHARM

Other Exchanges 8RP:Germany

Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092

Website http://www.celonpharma.com

Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.

48GF Score

Get the complete analysis for WAR:CLN

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł19.78

Price

zł23.11

GF Value

View WAR:CLN Analysis

See LT-Debt-to-Total-Asset data for all stocks →